Company intelligence / Profile preview

Oncostellae

Ownership: Private
Development stage: Phase 2

Overview

Oncostellae has advanced a novel GI-targeted JAK inhibitor and a non-steroidal full antagonist of the glucocorticoid receptor into clinical trials. The lead program OST‐499 is currently in a Phase I trial for colorectal cancer and other solid tumors. The company’s model focuses on developing candidates through early clinical proof-of-concept before licensing to larger pharmaceutical partners for further development and commercialization.

Therapeutic areas: OncologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

OST-122

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Oncostellae.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncostellae.

Explore the full profile